VetrixBio

Today at the 6th International Veterinary Pain Short Course hosted at NC State College of Veterinary Medicine, VetrixBio presented the first clinical data for VTX-304, its investigational bispecific antibody designed…

VetrixBio today highlighted the strength of its leadership and advisory team, bringing together experience across biotechnology, veterinary medicine, and drug development. The company is supported by a group of advisors with…

VetrixBio today announced preliminary safety and efficacy data from its first in vivo study of VTX-304, the company’s lead program for osteoarthritis in dogs. The study, conducted in a natural…

VetrixBio today provided an update on its oncology program, highlighting continued progress in the development of VTX-301/302, a localized immunotherapy combination for the treatment of cancer in companion animals. The program…

VetrixBio today highlighted its development strategy in osteoarthritis, centered on a dual-target biologic approach designed to address both pain and the underlying progression of disease. Osteoarthritis is one of the…

Graham Lumsden and Peter Hanson today announced the formation of VetrixBio, a biotechnology company focused on developing novel therapies for companion animals. VetrixBio was founded on a simple premise: pets…